Clinical trial / 2018
Chronic nicotinamide riboside supplementation is well-tolerated and stimulates NAD+ metabolism in healthy middle-aged and older adults.
In a 2 x 6-week randomized, double-blind, placebo-controlled crossover clinical trial, researchers assessed the effects of chronic supplementation with the NAD+ precursor nicotinamide riboside (NR) in healthy middle-aged and older adults. Chronic NR supplementation was well tolerated and effectively stimulated NAD+ metabolism. The results suggest that future clinical trials should further evaluate the potential benefits of NR for reducing blood pressure and arterial stiffness in this population.
- Study type
- 2 x 6-week randomized, double-blind, placebo-controlled crossover trial
- Who was studied
- Healthy middle-aged and older adults
- What was measured
- Tolerability, stimulation of NAD+ metabolism, and physiological function
THE PAPER
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.
Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Nat Commun, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.